Serial entrepreneur Michael Heltzen, CEO of eXoZymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, eXoZymes isolates enzymatic pathways to work as pure chemistry — achieving engineering-level control previously deemed impossible in conventional synthetic biology.

Michael discusses eXoZymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting.

🎧 Simplecast:

https://inside-biotech.simplecast.com/episodes/revolutionizing-biotechnology-with-exozymes-michael-heltzen

🎧 Apple Podcast:

https://podcasts.apple.com/us/podcast/inside-biotech/id1550384354?i=1000729544649

📺 Spotify (Video Podcast):

https://open.spotify.com/episode/3YbDB6jXEi1ge2lmh2XRP7?si=5Ah8o4udRvqamGQk4MieuQ